Cytosorbents (NASDAQ:CTSO) CEO Phillip Chan Buys 200,000 Shares

Cytosorbents Corporation (NASDAQ:CTSO) CEO Phillip Chan acquired 200,000 shares of the company’s stock in a transaction on Friday, September 4th. The shares were purchased at an average cost of $0.35 per share, with a total value of $70,000.00. Following the completion of the acquisition, the chief executive officer directly owned 1,944,432 shares in the company, valued at approximately $680,551.20. The trade was a 11.47% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Cytosorbents Stock Performance

Cytosorbents stock opened at $6.33 on Thursday. The company has a current ratio of 0.66, a quick ratio of 0.50 and a debt-to-equity ratio of 4.70. Cytosorbents Corporation has a 1 year low of $6.00 and a 1 year high of $20.40. The company has a market cap of $19.95 million, a PE ratio of -1.09 and a beta of 1.34. The company’s 50-day moving average is $7.35 and its two-hundred day moving average is $10.04.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.73. The company had revenue of $9.63 million during the quarter, compared to analysts’ expectations of $9.38 million. Cytosorbents had a negative net margin of 48.94% and a negative return on equity of 431.65%. Equities analysts anticipate that Cytosorbents Corporation will post -4.4 earnings per share for the current year.

Institutional Investors Weigh In On Cytosorbents

Large investors have recently bought and sold shares of the company. Avenir Corp grew its holdings in shares of Cytosorbents by 2.9% in the 4th quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock valued at $3,343,000 after buying an additional 147,261 shares during the period. CIBC Bancorp USA Inc. acquired a new stake in Cytosorbents during the 3rd quarter worth $161,000. Citadel Advisors LLC lifted its holdings in Cytosorbents by 127.3% during the third quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock worth $61,000 after acquiring an additional 36,790 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Cytosorbents by 3.7% during the third quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after acquiring an additional 79,535 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in Cytosorbents by 149.2% in the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after acquiring an additional 37,519 shares during the period. Institutional investors own 32.87% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a research report on Monday, July 6th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Cytosorbents presently has an average rating of “Hold” and an average price target of $107.50.

About Cytosorbents

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.